Initial Approval: January 8, 2014

CRITERIA FOR PRIOR AUTHORIZATION

Neumega® (oprelvekin)

PROVIDER GROUP Pharmacy

Professional

MANUAL GUIDELINES The following drug requires prior authorization:

Oprelvekin (Neumega)

CRITERIA FOR NEUMEGA: (must meet all of the following)

• Patient must have a non-myeloid malignancy (non-myeloid malignancies include all types of carcinoma, all types of sarcoma, melanoma, lymphomas, lymphocytic leukemias (ALL and CLL), and multiple myeloma)

Patient must be receiving myelosuppressive chemotherapy

• Patient must be at high risk of thrombocytopenia (e.g. patients who have experienced severe thrombocytopenia following a previous chemotherapy cycle)

LENGTH OF APPROVAL 12 months